Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2012, Article ID 381029, 32 pages
http://dx.doi.org/10.1155/2012/381029
Review Article

Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models

Clemens Schöpf-Institute of Organic Chemistry and Biochemistry, Technische Universität Darmstadt, 64287 Darmstadt, Germany

Received 8 December 2011; Accepted 31 January 2012

Academic Editor: Kurt A. Jellinger

Copyright © 2012 Thomas Kramer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. K. Chico, L. J. van Eldik, and D. M. Watterson, “Targeting protein kinases in central nervous system disorders,” Nature Reviews Drug Discovery, vol. 8, no. 11, pp. 892–909, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Bossemeyer, “Protein kinases—structure and function,” The FEBS Letters, vol. 369, no. 1, pp. 57–61, 1995. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Peifer and D. R. Alessi, “Small-molecule inhibitors of PDK1,” ChemMedChem, vol. 3, no. 12, pp. 1810–1838, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Hooper, R. Killick, and S. Lovestone, “The GSK3 hypothesis of Alzheimer's disease,” Journal of Neurochemistry, vol. 104, no. 6, pp. 1433–1439, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Ferrer, T. Gomez-Isla, B. Puig et al., “Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies,” Current Alzheimer Research, vol. 2, no. 1, pp. 3–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Hernandez, E. Gomez de Barreda, A. Fuster-Matanzo, J. J. Lucas, and J. Avila, “GSK3: a possible link between beta amyloid peptide and tau protein,” Experimental Neurology, vol. 223, no. 2, pp. 322–325, 2010. View at Publisher · View at Google Scholar
  7. A. Leroy, I. Landrieu, I. Huvent et al., “Spectroscopic studies of GSKβ phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E,” The Journal of Biological Chemistry, vol. 285, no. 43, pp. 33435–33444, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Martinez, A. Castro, I. Dorronsoro, and M. Alonso, “Glycogen synthase kinase-3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation,” Medicinal Research Reviews, vol. 22, no. 4, pp. 373–384, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Eldar-Finkelman, “Glycogen synthase kinase-3: an emerging therapeutic target,” Trends in Molecular Medicine, vol. 8, no. 3, pp. 126–132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Frame and P. Cohen, “GSK3 takes centre stage more than 20 years after its discovery,” Biochemical Journal, vol. 359, no. 1, pp. 1–16, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Alzheimer, “Über eine eigenartige Erkrankung der Hirnrinde,” Allgemeine Zeitschrift für Psychiatrie und psychisch-gerichtiliche Medizin, vol. 64, pp. 146–148, 1907. View at Google Scholar
  12. R. A. Stelzmann, H. N. Schnitzlein, and F. R. Murtagh, “An English translation of Alzheimer's 1907 paper, 'uber eine eigenartige erkankung der hirnrinde',” Clinical Anatomy, vol. 8, no. 6, pp. 429–431, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Dickson, Weller R. O. et al., Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, Wiley-Blackwell, 2nd edition, 2011.
  14. C. Duyckaerts, B. Delatour, and M. C. Potier, “Classification and basic pathology of Alzheimer disease,” Acta Neuropathologica, vol. 118, no. 1, pp. 5–36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. P. Mazanetz and P. M. Fischer, “Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases,” Nature Reviews Drug Discovery, vol. 6, no. 6, pp. 464–479, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Hernández and J. Avila, “The role of glycogen synthase kinase-3 in the early stages of Alzheimers' disease,” The FEBS Letters, vol. 582, no. 28, pp. 3848–3854, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Cohen and M. Goedert, “GSK3 inhibitors: development and therapeutic potential,” Nature Reviews Drug Discovery, vol. 3, no. 6, pp. 479–487, 2004. View at Google Scholar · View at Scopus
  18. L. Sereno, M. Coma, M. Rodriguez et al., “A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo,” Neurobiology of Disease, vol. 35, no. 3, pp. 359–367, 2009. View at Publisher · View at Google Scholar
  19. A. Takashima, “Drug development targeting the glycogen synthase kinase-β(GSK- 3β)-mediated signal transduction pathway: role of GSK-β in adult brain,” Journal of Pharmacological Sciences, vol. 109, no. 2, pp. 174–178, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Spittaels, C. van den Haute, J. van Dorpe et al., “Glycogen synthase kinase-β phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice,” The Journal of Biological Chemistry, vol. 275, no. 52, pp. 41340–41349, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. R. V. Bhat, S. L. Budd Haeberlein, and J. Avila, “Glycogen synthase kinase-3: a drug target for CNS therapies,” Journal of Neurochemistry, vol. 89, no. 6, pp. 1313–1317, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Feng, Y. Geisselbrecht, S. Blanck et al., “Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors,” Journal of the American Chemical Society, vol. 133, no. 15, pp. 5976–5986, 2011. View at Publisher · View at Google Scholar
  23. H. Eldar-Finkelman, A. Licht-Murava, S. Pietrokovski, and M. Eisenstein, “Substrate competitive GSK-3 Inhibitors—strategy and Implications,” Biochimica et Biophysica Acta, vol. 1804, no. 3, pp. 598–603, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Martinez, M. Alonso, A. Castro, C. Perez, and F. J. Moreno, “First non-ATP competitive glycogen synthase kinase-3β (GSK-β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease,” Journal of Medicinal Chemistry, vol. 45, no. 6, pp. 1292–1299, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Martinez, “Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs,” Medicinal Research Reviews, vol. 28, no. 5, pp. 773–796, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Mora, G. Sabio, R. A. Gonzalez-Polo et al., “Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells,” Journal of Neurochemistry, vol. 78, no. 1, pp. 199–206, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. W. J. Ryves and A. J. Harwood, “Lithium inhibits glycogen synthase kinase-3 by competition for magnesium,” Biochemical and Biophysical Research Communications, vol. 280, no. 3, pp. 720–725, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Bax, P. S. Carter, C. Lewis et al., “The structure of phosphorylated GSK-β complexed with a peptide, FRATtide, that inhibits β-catenin phosphorylation,” Structure, vol. 9, no. 12, pp. 1143–1152, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. J. M. Domínguez, A. Fuertes, L. Orozco, M. del Monte-Millán, E. Delgado, and M. Medina, “Evidence for the irreversible inhibition of glycogen synthase kinas-3β by tideglusib,” The Journal of Biological Chemistry, vol. 287, pp. 893–904, 2012. View at Publisher · View at Google Scholar
  30. D. G. Smith, M. Buffet, A. E. Fenwick et al., “3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3),” Bioorganic and Medicinal Chemistry Letters, vol. 11, no. 5, pp. 635–639, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. J. A. Bertrand, S. Thieffine, A. Vulpetti et al., “Structural characterization of the GSK-β active site using selective and non-selective ATP-mimetic inhibitors,” Journal of Molecular Biology, vol. 333, no. 2, pp. 393–407, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. P. Coghlan, A. A. Culbert, D. A. E. Cross et al., “Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription,” Chemistry and Biology, vol. 7, no. 10, pp. 793–803, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. D. A. E. Cross, A. A. Culbert, K. A. Chalmers, L. Facci, S. D. Skaper, and A. D. Reith, “Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death,” Journal of Neurochemistry, vol. 77, no. 1, pp. 94–102, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. M. L. Selenica, H. S. Jensen, A. K. Larsen et al., “Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation,” British Journal of Pharmacology, vol. 152, no. 6, pp. 959–979, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. D. J. O'Neill, L. Shen, C. Prouty et al., “Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-β (GSK-β) inhibitors,” Bioorganic and Medicinal Chemistry, vol. 12, no. 12, pp. 3167–3185, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. H. C. Zhang, H. Ye, B. R. Conway et al., “3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 12, pp. 3245–3250, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. T. A. Engler, J. R. Henry, S. Malhotra et al., “Substituted 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-[1,4] diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3,” Journal of Medicinal Chemistry, vol. 47, no. 16, pp. 3934–3937, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. T. A. Engler, S. Malhotra, T. P. Burkholder et al., “The development of potent and selective bisarylmaleimide GSK3 inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 4, pp. 899–903, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. Q. Ye, G. Xu, D. Lv, Z. Cheng, J. Li, and Y. Hu, “Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-β (GSK-β) inhibitors,” Bioorganic and Medicinal Chemistry, vol. 17, no. 13, pp. 4302–4312, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Gong, D. Hirschfeld, Y. C. Tan et al., “Discovery of potent and bioavailable GSK-β inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 5, pp. 1693–1696, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. D. I. Perez, V. Palomo, C. Perez et al., “Switching reversibility to irreversibility in glycogen synthase kinase-3 inhibitors: clues for specific design of new compounds,” Journal of Medicinal Chemistry, vol. 54, no. 12, pp. 4042–4056, 2011. View at Publisher · View at Google Scholar
  42. I. Hers, J. M. Tavare, and R. M. Denton, “The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity,” The FEBS Letters, vol. 460, no. 3, pp. 433–436, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. G. H. Kuo, C. Prouty, A. de Angelis et al., “Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-β inhibitors,” Journal of Medicinal Chemistry, vol. 46, no. 19, pp. 4021–4031, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. H. C. Zhang, K. B. White, H. Ye et al., “Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 18, pp. 3049–3053, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Shen, C. Prouty, B. R. Conway et al., “Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-β (GSK-β) inhibitors,” Bioorganic and Medicinal Chemistry, vol. 12, no. 5, pp. 1239–1255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. H. C. Zhang, L. V. R. Bonaga, H. Ye, C. K. Derian, B. P. Damiano, and B. E. Maryanoff, “Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 10, pp. 2863–2868, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. A. P. Kozikowski, I. N. Gaisina, H. Yuan et al., “Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. Possible new GSK-β therapies for bipolar disorders,” Journal of the American Chemical Society, vol. 129, no. 26, pp. 8328–8332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. I. N. Gaisina, F. Gallier, A. V. Ougolkov et al., “From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase-β inhibitors that suppress proliferation and survival of pancreatic cancer cells,” Journal of Medicinal Chemistry, vol. 52, no. 7, pp. 1853–1863, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Zhong, H. Zou, M. V. Semenov et al., “Characterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling,” Molecular Biosystems, vol. 5, no. 11, pp. 1356–1360, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Zou, L. Zhou, Y. Li et al., “Benzo[e]isoindole-1,3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). Synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode,” Journal of Medicinal Chemistry, vol. 53, no. 3, pp. 994–1003, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Kozikowski and I. Gaysina, “3-Benzofuranyl-4-indolyl maleimides as potent GSK3 inhibitors for neurogenerative disorders,” WO 2008/077138 A1, 2008. View at Google Scholar
  52. A. Kozikowski and I. Gaysina, “Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors,” US 2010/0004308 A1, 2010. View at Google Scholar
  53. P. von Matt and J. Wagner, “Indolylmaleimide derivatives,” EP 2075249 A2, Novartis AG., 2009. View at Google Scholar
  54. H. Zhang, B. Maryanoff, and H. Ye, “Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors,” US 7439363 B2, Janssen Pharmaceutica N.V., 2008. View at Google Scholar
  55. H. Zhang, B. Maryanoff, and H. Ye, “Substituted indazolyl (indolyl) maleimide derivatives as kinase inhibitors,” EP 1654255 B1, Janssen Pharmaceutica N.V., 2008. View at Google Scholar
  56. S. Omura, Y. Iwai, A. Hirano et al., “A new alkaloid AM 2282 of Streptomyces origin taxonomy, fermentation, isolation and preliminary characterization,” Journal of Antibiotics, vol. 30, no. 4, pp. 275–282, 1977. View at Google Scholar
  57. N. Funato, H. Takayanagi, Y. Konda et al., “Absolute configuration of staurosporine by X-ray analysis,” Tetrahedron Letters, vol. 35, no. 8, pp. 1251–1254, 1994. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Leclerc, M. Garnier, R. Hoessel et al., “Indirubins inhibit glycogen synthase kinase-β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?” The Journal of Biological Chemistry, vol. 276, no. 1, pp. 251–260, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Bregman, D. S. Williams, G. E. Atilla, P. J. Carroll, and E. Meggers, “An organometallic inhibitor for glycogen synthase kinase-3,” Journal of the American Chemical Society, vol. 126, no. 42, pp. 13594–13595, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. G. E. Atilla-Gokcumen, D. S. Williams, H. Bregman, N. Pagano, and E. Meggers, “Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase-3,” ChemBioChem, vol. 7, no. 9, pp. 1443–1450, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. G. E. Atilla-Gokcumen, N. Pagano, C. Streu et al., “Extremely tight binding of a ruthenium complex to glycogen synthase kinase-3,” ChemBioChem, vol. 9, no. 18, pp. 2933–2936, 2008. View at Google Scholar · View at Scopus
  62. G. E. Atilla-Gokcumen, L. di Costanzo, and E. Meggers, “Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase-3β,” Journal of Biological Inorganic Chemistry, vol. 16, no. 1, pp. 45–50, 2011. View at Publisher · View at Google Scholar
  63. L. Meijer, A. L. Skaltsounis, P. Magiatis et al., “GSK-3-selective inhibitors derived from Tyrian purple indirubins,” Chemistry and Biology, vol. 10, no. 12, pp. 1255–1266, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Polychronopoulos, P. Magiatis, A. L. Skaltsounis et al., “Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases,” Journal of Medicinal Chemistry, vol. 47, no. 4, pp. 935–946, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Vougogiannopoulou, Y. Ferandin, K. Bettayeb et al., “Soluble 3′,6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase-3 alter circadian period,” Journal of Medicinal Chemistry, vol. 51, no. 20, pp. 6421–6431, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Beauchard, H. Laborie, H. Rouillard et al., “Synthesis and kinase inhibitory activity of novel substituted indigoids,” Bioorganic and Medicinal Chemistry, vol. 17, no. 17, pp. 6257–6263, 2009. View at Publisher · View at Google Scholar
  67. D. Beher, M. Bettai, I. Churcher et al., “1-alkyl-3-thio-substituted indole-2-alkynoic acids useful for the treatment for Alzheimer's disease and related conditions,” EP 1708997 B1, Merck and Company, Inc., 2009. View at Google Scholar
  68. S. Berg, S. Hellberg, M. Nylöf, and Y. Xue, “3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3,” US 7399780 B2, Astra Zeneca AB., 2008. View at Google Scholar
  69. S. Berg, S. Hellberg, M. Nylöf, and Y. Xue, “2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors,” EP 1492785 B1, Astra Zeneca AB., 2008. View at Google Scholar
  70. J. Green, A. Miller, J. Jimenez et al., “Azaindoles useful as inhibitors of rock and other protein kinases,” US 7514448 B2, Vertex Pharmaceuticals Inc., 2009. View at Google Scholar
  71. A. Heckel, G. Roth, J. Kley, S. Hoerer, and I. Uphues, “Novel alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products,” WO 2005/087727 A1, Boehringer Ingelheim Pharma GmbH & Company KG., 2005. View at Google Scholar
  72. A. Heckel, G. Roth, J. Kley, S. Hoerer, and I. Uphues, “Cycloalkyl—containing 5-acylindolinones, the preparation thereof and their use as medicaments,” WO 7262206 B2, Boehringer Ingelheim International GmbH., 2007. View at Google Scholar
  73. A. Heckel, G. Roth, J. Kley, S. Hoerer, and I. Uphues, “Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments,” US 7176231 B2, Boehringer Ingelheim International GmbH., 2007. View at Google Scholar
  74. A. Heckel, G. Roth, J. Kley, S. Hoerer, and I. Uphues, “Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments,” US 7560480 B2, Boehringer Ingelheim Pharma GmbH & Company KG., 2009. View at Google Scholar
  75. L. Meijer, P. Greengard, M. Knockaert, and A. Skaltsounis, “Indirubin-type compounds, compositions, and methods for their use,” US 2007/0276025 A1, 2007. View at Google Scholar
  76. M. Leost, C. Schultz, A. Link et al., “Paullones are potent inhibitors of glycogen synthase kinase-β and cyclin-dependent kinase 5/p25,” European Journal of Biochemistry, vol. 267, no. 19, pp. 5983–5994, 2000. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Schultz, A. Link, M. Leost et al., “Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity,” Journal of Medicinal Chemistry, vol. 42, no. 15, pp. 2909–2919, 1999. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Knockaert, K. Wieking, S. Schmitt et al., “Intracellular targets of paullones: identification following affinity purification on immobilized inhibitor,” The Journal of Biological Chemistry, vol. 277, no. 28, pp. 25493–25501, 2002. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Kunick, K. Lauenroth, M. Leost, L. Meijer, and T. Lemcke, “1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-β,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 2, pp. 413–416, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. C. Kunick, Z. Zeng, R. Gussio et al., “Structure-aided of optimization of kinase inhibitors derived from alsterpaullone,” ChemBioChem, vol. 6, no. 3, pp. 541–549, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Meijer and C. Kunick, “Use of paullone derivatives for making medicines,” WO 2001/060374 A1, 2001. View at Google Scholar
  82. J. Witherington, V. Bordas, S. L. Garland et al., “5-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3),” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 9, pp. 1577–1580, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. J. Witherington, V. Bordas, D. Haigh et al., “5-Aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3),” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 9, pp. 1581–1584, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Witherington, V. Bordas, A. Gaiba et al., “6-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3),” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 18, pp. 3055–3057, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Witherington, V. Bordas, A. Gaiba et al., “6-Heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3),” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 18, pp. 3059–3062, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. Y. Uno, H. Iwashita, T. Tsukamoto et al., “Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice,” Brain Research, vol. 1296, pp. 148–163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. K. L. Kees, T. J. Caggiano, K. E. Steiner et al., “Studies on new acidic azoles as glucose-lowering agents in obese, diabetic db/db mice,” Journal of Medicinal Chemistry, vol. 38, no. 4, pp. 617–628, 1995. View at Google Scholar · View at Scopus
  88. K. L. Kees, J. J. Fitzgerald Jr., K. E. Steiner et al., “New potent antihyperglycemic agents in db/db mice: synthesis and structure-activity relationship studies of (4-substituted benzyl)(trifluoromethyl)pyrazoles and -pyrazolones,” Journal of Medicinal Chemistry, vol. 39, no. 20, pp. 3920–3928, 1996. View at Publisher · View at Google Scholar · View at Scopus
  89. G. R. Bebernitz, G. Argentieri, B. Battle et al., “The effect of 1,3-diaryl-[1H]-pyrazole-4-acetamides on glucose utilization in ob/ob mice,” Journal of Medicinal Chemistry, vol. 44, no. 16, pp. 2601–2611, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. D. M. Shen, E. J. Brady, M. R. Candelore et al., “Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 1, pp. 76–81, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. A. J. Peat, D. Garrido, J. A. Boucheron et al., “Novel GSK-3 inhibitors with improved cellular activity,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 9, pp. 2127–2130, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. C. Lum, J. Kahl, L. Kessler et al., “2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3),” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 12, pp. 3578–3581, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. A. M. Aronov, T. Qing, G. Martinez-Botella et al., “Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control,” Journal of Medicinal Chemistry, vol. 52, no. 20, pp. 6362–6368, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. D. B. Ring, K. W. Johnson, E. J. Henriksen et al., “Selective glycogen synthase kinase-3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo,” Diabetes, vol. 52, no. 3, pp. 588–595, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. Y. Maeda, M. Nakano, H. Sato et al., “4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 15, pp. 3907–3911, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. Y. Miyazaki, Y. Maeda, H. Sato, M. Nakano, and G. W. Mellor, “Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 6, pp. 1967–1971, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Bebbington, Binch H., R. Knegtel et al., “Pyrazole compounds useful as protein kinase inhibitors,” US 6660731 B2, Vertex Pharmaceuticals Inc., 2003. View at Google Scholar
  98. D. Bebbington, H. Binch, R. Knegtel et al., “Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors,” US 7008948 B2, Vertex Pharmaceuticals Inc., 2006. View at Google Scholar
  99. D. Bebbington and J. Charrier, “Pyrazole compounds useful as protein kinase inhibitors,” US 6656939 B2, Vertex Pharmaceuticals Inc., 2003. View at Google Scholar
  100. D. Bebbington, J. Charrier, R. Davies et al., “Pyrazole compounds useful as protein kinase inhibitors,” US 6989385 B2, Vertex Pharmaceuticals Inc., 2006. View at Google Scholar
  101. D. Bebbington, J. Charrier, R. Davies et al., “Pyrazole compounds useful as protein kinase inhibitors,” WO 2002/059111 A2, Vertex Pharmaceuticals Inc., 2002. View at Google Scholar
  102. D. Bebbington, J. Charrier, R. Davies et al., “Pyrazole compounds useful as protein kinase inhibitors,” US 6653301 B2, Vertex Pharmaceuticals Inc., 2003. View at Google Scholar
  103. D. Bebbington, J. Charrier, J. Golec, A. Miller, and R. Knegtel, “Pyrazole compounds useful as protein kinase inhibitors,” WO 2002/057259 A2, Vertex Pharmaceuticals Inc., 2002. View at Google Scholar
  104. D. Bebbington, J. Charrier, J. Golec, A. Miller, and R. Knegtel, “Pyrazole compounds useful as protein kinase inhibitors,” US 6664247 B2, Vertex Pharmaceuticals Inc., 2003. View at Google Scholar
  105. D. Bebbington, J. Charrier, J. Golec, and F. Pierard, “Pyrazole compounds useful as protein kinase inhibitors,” US 6727251 B2, Vertex Pharmaceuticals Inc., 2004. View at Google Scholar
  106. D. Bebbington, J. Charrier, J. Golec, and F. Pierard, “Pyrazole compounds useful as protein kinase inhibitors,” US 7427681 B2, Vertex Pharmaceuticals Inc., 2008. View at Google Scholar
  107. R. Davies, D. Bebbington, R. Knegtel et al., “Fusion joining device for plastic tubes,” US 39081 B2, Vertex Pharmaceuticals Inc., 2008. View at Google Scholar
  108. R. Davies, P. Li, J. Golec, J. Charrier, R. Knegtel, and D. Bebbington, “Pyrazole compounds useful as protein kinase inhibitors,” US 6610677 B2, Vertex Pharmaceuticals Inc., 2003. View at Google Scholar
  109. E. Freyne, C. Love, L. Cooymans et al., “Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors,” US 7449465 B2, Janssen Pharmaceutica, 2008. View at Google Scholar
  110. E. Freyne, C. Love, L. Cooymans et al., “Triazolopyrimidine derivatives as glycogen synthase kinase-3 inhibitors,” US 7560458 B2, Janssen Pharmaceutica, 2009. View at Google Scholar
  111. A. Garcia, T. Gallet, A. Taki Li et al., “2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives,” US 7566720 B2, Sanofi-Aventis Mitsubishi Pharma Corporation, 2009. View at Google Scholar
  112. P. George, A. Lochead, M. Saady, F. Slowinski, and P. Yaiche, “Substituted 8′-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one and 8′-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one derivatives,” US 7507743 B2, Sanofi-Aventis Mitsubishi Pharma Corporation, 2009. View at Google Scholar
  113. D. Goff, S. Harrison, J. Nuss, D. Ring, and X. Zhou, “Inhibitors of glycogen synthase kinase 3,” US 6417185 B1, Chiron Corporation, 2002. View at Google Scholar
  114. K. Kataoka, T. Kosugi, T. Ishii et al., “Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors,” US 7528140 B2, Teijin Limited, 2009. View at Google Scholar
  115. K. Kataoka, T. Kosugi, T. Ishii et al., “Pyrrolopyrimidine derivative,” EP 1477490 A1, Teijin Limited, 2004. View at Google Scholar
  116. R. Knegtel, D. Bebbington, H. Binch et al., “Pyrazole compounds useful as protein kinase inhibitors,” US 6613776 B2, Vertex Pharmaceuticals Inc., 2003. View at Google Scholar
  117. A. Lochead, S. Marguerie, M. Saady, and P. Yaiche, “1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives,” US 7608624 B2, Sanofi-Aventis Mitsubishi Pharma Corporation, 2009. View at Google Scholar
  118. M. Nakano and Y. Maeda, “Novel chemical compounds,” WO 2005/061516 A1, Smithkline Beecham Corporation, 2005. View at Google Scholar
  119. J. Nuss, S. Harrison, D. Ring et al., “Inhibitors of glycogen synthase kinase-3,” US 6489344 B1, Chiron Corporation, 2002. View at Google Scholar
  120. J. Nuss, S. Harrison, D. Ring et al., “Inhibitors of glycogen synthase kinase-3,” US 7037918 B2, Chiron Corporation, 2006. View at Google Scholar
  121. J. Nuss, S. Harrison, D. Ring et al., “Inhibitors of glycogen synthase kinase-3,” US 7045519 B2, Chiron Corporation, 2006. View at Google Scholar
  122. T. Tsutsumi, S. Sugiura, M. Koga et al., “Substituted pyrrolo[3,2-d]pyrimidine derivatives,” US 7557113 B2, Teijin Pharma Limited, 2009. View at Google Scholar
  123. P. H. Olesen, A. R. Sorensen, B. Urso et al., “Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors,” Journal of Medicinal Chemistry, vol. 46, no. 15, pp. 3333–3341, 2003. View at Publisher · View at Google Scholar · View at Scopus
  124. U. Bandarage, B. Hare, J. Parsons et al., “4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: potent and selective p70S6 kinase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 17, pp. 5191–5194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. M. Saitoh, J. Kunitomo, E. Kimura et al., “Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-β,” Bioorganic and Medicinal Chemistry, vol. 17, no. 5, pp. 2017–2029, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. M. Saitoh, J. Kunitomo, E. Kimura et al., “2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-β with good brain permeability,” Journal of Medicinal Chemistry, vol. 52, no. 20, pp. 6270–6286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  127. T. Onishi, H. Iwashita, Y. Uno et al., “A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)- methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease,” Journal of Neurochemistry, vol. 119, no. 6, pp. 1330–1340, 2011. View at Publisher · View at Google Scholar
  128. M. A. Khanfar, R. A. Hill, A. Kaddoumi, and K. A. El Sayed, “Discovery of novel GSK-β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening,” Journal of Medicinal Chemistry, vol. 53, no. 24, pp. 8534–8545, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. A. G. Koryakova, Y. A. Ivanenkov, E. A. Ryzhova et al., “Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamides as selective GSK-3 inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 12, pp. 3661–3666, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. C. Loge, A. Testard, V. Thiery et al., “Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: synthesis, biological evaluation and molecular modeling studies,” European Journal of Medicinal Chemistry, vol. 43, no. 7, pp. 1469–1477, 2008. View at Publisher · View at Google Scholar · View at Scopus
  131. R. Bhat, Y. Xue, S. Berg et al., “tructural insights and biological effects of glycogen synthase kinase-3-specific inhibitor AR-A014418,” The Journal of Biological Chemistry, vol. 278, no. 46, pp. 45937–45945, 2003. View at Publisher · View at Google Scholar
  132. W. Noble, E. Planel, C. Zehr et al., “Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 19, pp. 6990–6995, 2005. View at Publisher · View at Google Scholar · View at Scopus
  133. F. Lo Monte, T. Kramer, A. Bolander et al., “Synthesis and biological evaluation of glycogen synthase kinase-3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 18, pp. 5610–5615, 2011. View at Publisher · View at Google Scholar
  134. D. Shin, S. C. Lee, Y. S. Heo et al., “Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-β,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 20, pp. 5686–5689, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. B. Voigt, M. Krug, C. Schachtele, F. Totzke, and A. Hilgeroth, “Probing novel 1-aza-9-oxafluorenes as selective GSK-β inhibitors,” ChemMedChem, vol. 3, no. 1, pp. 120–126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. N. B. Chauhan, G. J. Siegel, and D. L. Feinstein, “Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576,” Neuropharmacology, vol. 48, no. 1, pp. 93–104, 2005. View at Publisher · View at Google Scholar · View at Scopus
  137. M. Arnost, A. Pierce, E. ter Haar et al., “3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: highly ligand efficient and potent inhibitors of GSKβ,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 5, pp. 1661–1664, 2010. View at Publisher · View at Google Scholar · View at Scopus
  138. W. Chen, I. N. Gaisina, H. Gunosewoyo et al., “Structure-guided design of a highly selective glycogen synthase kinase-3β inhibitor: a superior neuroprotective pyrazolone showing antimania effects,” ChemMedChem, vol. 6, pp. 1587–1592, 2011. View at Google Scholar
  139. M. A. Khanfar, B. A. Asal, M. Mudit, A. Kaddoumi, and K. A. El Sayed, “The marine natural-derived inhibitors of glycogen synthase kinase-β phenylmethylene hydantoins: in vitro and in vivo activities and pharmacophore modeling,” Bioorganic and Medicinal Chemistry, vol. 17, no. 16, pp. 6032–6039, 2009. View at Publisher · View at Google Scholar · View at Scopus
  140. K. Coffman, M. Brodney, J. Cook et al., “6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3β inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 21, pp. 1429–1433, 2011. View at Google Scholar
  141. M. Hamann, D. Alonso, E. Martin-Aparicio et al., “Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease,” Journal of Natural Products, vol. 70, no. 9, pp. 1397–1405, 2007. View at Publisher · View at Google Scholar
  142. M. Gompel, M. Leost, E. B. de Kier Joffe et al., “Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 7, pp. 1703–1707, 2004. View at Publisher · View at Google Scholar · View at Scopus
  143. L. Meijer, A. M. W. H. Thunnissen, A. W. White et al., “Inhibition of cyclin-dependent kinases, GSK-β and CK1 by hymenialdisine, a marine sponge constituent,” Chemistry and Biology, vol. 7, no. 1, pp. 51–63, 2000. View at Publisher · View at Google Scholar · View at Scopus
  144. N. Zhang, R. Zhong, H. Yan, and Y. Jiang, “Structural features underlying selective inhibition of GSK3β by dibromocantharelline: implications for rational drug design,” Chemical Biology and Drug Design, vol. 77, no. 3, pp. 199–205, 2011. View at Publisher · View at Google Scholar
  145. V. Pande and M. J. Ramos, “Structural basis for the GSK-β binding affinity and selectivity against CDK-2 of 1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1H-[1,2,3] triazole-4-carboxylic acid derivatives,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 23, pp. 5129–5135, 2005. View at Publisher · View at Google Scholar · View at Scopus
  146. E. ter Haar, J. T. Coll, D. A. Austen, H. M. Hsiao, L. Swenson, and J. Jain, “Structure of GSKβ reveals a primed phosphorylation mechanism,” Nature Structural Biology, vol. 8, no. 7, pp. 593–596, 2001. View at Publisher · View at Google Scholar · View at Scopus
  147. J. Gotz and L. M. Ittner, “Animal models of Alzheimer's disease and frontotemporal dementia,” Nature Reviews Neuroscience, vol. 9, no. 7, pp. 532–544, 2008. View at Publisher · View at Google Scholar · View at Scopus
  148. K. Iijima-Ando and K. Iijima, “Transgenic drosophila models of Alzheimer's disease and tauopathies,” Brain Structure and Function, vol. 214, no. 2-3, pp. 245–262, 2010. View at Publisher · View at Google Scholar
  149. J. Wentzell and D. Kretzschmar, “Alzheimer's disease and tauopathy studies in flies and worms,” Neurobiology of Disease, vol. 40, no. 1, pp. 21–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  150. J. J. Lucas, F. Hernandez, P. Gomez-Ramos, M. A. Moran, R. Hen, and J. Avila, “Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice,” The EMBO Journal, vol. 20, no. 1-2, pp. 27–39, 2001. View at Google Scholar
  151. M. Perez, E. Ribe, A. Rubio et al., “Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation,” Neuroscience, vol. 130, no. 2, pp. 339–347, 2005. View at Publisher · View at Google Scholar
  152. E. M. Ribe, M. Perez, B. Puig et al., “Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice,” Neurobiology of Disease, vol. 20, no. 3, pp. 814–822, 2005. View at Publisher · View at Google Scholar
  153. D. Terwel, D. Muyllaert, I. Dewachter et al., “Amyloid activates GSK-β to aggravate neuronal tauopathy in bigenic mice,” American Journal of Pathology, vol. 172, no. 3, pp. 786–798, 2008. View at Publisher · View at Google Scholar · View at Scopus
  154. J. Lewis, D. W. Dickson, W. L. Lin et al., “Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP,” Science, vol. 293, no. 5534, pp. 1487–1491, 2001. View at Publisher · View at Google Scholar · View at Scopus
  155. S. Oddo, A. Caccamo, J. D. Shepherd et al., “Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction,” Neuron, vol. 39, no. 3, pp. 409–421, 2003. View at Publisher · View at Google Scholar · View at Scopus
  156. J. Lewis, E. McGowan, J. Rockwood et al., “Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L)tau protein,” Nature Genetics, vol. 25, no. 4, pp. 402–405, 2000. View at Publisher · View at Google Scholar · View at Scopus
  157. D. Paquet, R. Bhat, A. Sydow et al., “A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation,” Journal of Clinical Investigation, vol. 119, no. 5, pp. 1382–1395, 2009. View at Publisher · View at Google Scholar
  158. D. Paquet, B. Schmid, and C. Haass, “Transgenic zebrafish as a novel animal model to study tauopathies and other neurodegenerative disorders in vivo,” Neurodegenerative Diseases, vol. 7, no. 1–3, pp. 99–102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  159. Y. Okawa, K. Ishiguro, and S. C. Fujita, “Stress-induced hyperphosphorylation of tau in the mouse brain,” The FEBS Letters, vol. 535, no. 1–3, pp. 183–189, 2003. View at Publisher · View at Google Scholar · View at Scopus
  160. S. Yoshida, M. Maeda, S. Kaku, H. Ikeya, K. Yamada, and S. Nakaike, “Lithium inhibits stress-induced changes in tau phosphorylation in the mouse hippocampus,” Journal of Neural Transmission, vol. 113, no. 11, pp. 1803–1814, 2006. View at Publisher · View at Google Scholar · View at Scopus
  161. K. Leroy and J. P. Brion, “Developmental expression and localization of glycogen synthase kinase-β in rat brain,” Journal of Chemical Neuroanatomy, vol. 16, no. 4, pp. 279–293, 1999. View at Publisher · View at Google Scholar · View at Scopus
  162. M. Takahashi, K. Tomizawa, and K. Ishiguro, “Distribution of tau protein kinase I/glycogen synthase kinase-β, phosphatases 2A and 2B, and phosphorylated tau in the developing rat brain,” Brain Research, vol. 857, no. 1-2, pp. 193–206, 2000. View at Publisher · View at Google Scholar · View at Scopus
  163. S. H. Min, J. S. Cho, J. H. Oh et al., “Tau and GSKβ dephosphorylations are required for regulating Pin1 phosphorylation,” Neurochemical Research, vol. 30, no. 8, pp. 955–961, 2005. View at Publisher · View at Google Scholar · View at Scopus
  164. N. Sato, L. Meijer, L. Skaltsounis, P. Greengard, and A. H. Brivanlou, “Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor,” Nature Medicine, vol. 10, no. 1, pp. 55–63, 2004. View at Publisher · View at Google Scholar · View at Scopus
  165. T. D. Gould, N. A. Gray, and H. K. Manji, “Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice,” Pharmacological Research, vol. 48, no. 1, pp. 49–53, 2003. View at Publisher · View at Google Scholar · View at Scopus
  166. A. Martinez, A. Castro, and M. Medina, Glycogen Synthase Kinase-3 (GSK-3) and Its Inhibitors, John Wiley & Sons, Hoboken, NJ, USA, 2006.
  167. A. Martinez, C. Gil, and D. I. Perez, “Glycogen synthase kinase-3 inhibitors in the next horizon for Alzheimer's disease treatment,” International Journal of Alzheimer's Disease, vol. 2011, Article ID 280502, 7 pages, 2011. View at Publisher · View at Google Scholar
  168. L. T. Alon, S. Pietrokovski, S. Barkan et al., “Selective loss of glycogen synthase kinase-3α in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation,” The FEBS Letters, vol. 585, no. 8, pp. 1158–1162, 2011. View at Publisher · View at Google Scholar
  169. C. J. Phiel, C. A. Wilson, V. M. Y. Lee, and P. S. Klein, “GSK-3α regulates production of Alzheimer's disease amyloid-β peptides,” Nature, vol. 423, no. 6938, pp. 435–439, 2003. View at Publisher · View at Google Scholar · View at Scopus
  170. M. I. Davis, J. P. Hunt, S. Herrgard et al., “Comprehensive analysis of kinase inhibitor selectivity,” Nature Biotechnology, vol. 29, no. 11, pp. 1046–1051, 2011. View at Publisher · View at Google Scholar
  171. D. Rauh, “Inaktive Kinasekonformationen stabilisieren,” Nachrichten aus der Chemie, vol. 58, no. 2, pp. 118–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. K. Okada, T. Sato, Y. Kohno, and M. Nomura, “7-Cycloalkylaminoquinolones as GSK-3 inhibitors,” WO 2010/104205 A1, Kyorin Pharmaceutical Company Limited, 2010. View at Google Scholar
  173. S. C. Turner, M. H. M. Bakker, W. Hornberger, and F. E. Wolter, “Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors,” WO 2010/109005 A1, Abbott GmbH & Co. KG., 2010. View at Google Scholar